Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Equity Income: 2019-2024

Historic Equity Income for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to -$1.8 million.

  • Pharming Group N.V's Equity Income rose 100.96% to $8,000 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.8 million, marking a year-over-year decrease of 51.82%. This contributed to the annual value of -$1.8 million for FY2024, which is 509.00% down from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Equity Income is -$1.8 million, which was down 509.00% from -$289,000 recorded in FY2023.
  • Pharming Group N.V's Equity Income's 5-year high stood at $694,000 during FY2021, with a 5-year trough of -$1.8 million in FY2024.
  • Over the past 3 years, Pharming Group N.V's median Equity Income value was -$1.1 million (recorded in 2022), while the average stood at -$1.0 million.
  • As far as peak fluctuations go, Pharming Group N.V's Equity Income spiked by 91.71% in 2021, and later slumped by 509.00% in 2024.
  • Pharming Group N.V's Equity Income (Yearly) stood at $362,000 in 2020, then spiked by 91.71% to $694,000 in 2021, then slumped by 256.05% to -$1.1 million in 2022, then soared by 73.31% to -$289,000 in 2023, then crashed by 509.00% to -$1.8 million in 2024.